Earnings Call · Q4 FY2022·2023-02-23

Q4 22EPS +14.04%·Rev n/aQ3 22EPS +5.36%·Rev n/aQ2 22EPS 0.00%·Rev n/aQ1 22EPS +5.77%·Rev n/a⚠ consensus missing

Kura Oncology, Inc. KURA

Pete De Spain — Investor Relations or Communications

Troy Wilson — President and Chief Executive Officer

Tom Doyle — Senior Vice President of Finance and Accounting

−2.1%1d on move date−2.0% vs SPY3d+2.5%5d+17.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KURA calls or request research access.

More KURA calls Browse calls Request research access